Fondazione Pisana per la Scienza-ONLUS, Pisa, Italy.
Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
Anticancer Res. 2019 Jul;39(7):3413-3418. doi: 10.21873/anticanres.13485.
One aim of cell-based in vitro assays is to identify the best drug candidate to develop using the best tumor cell model. This is challenging in every anticancer drug discovery process. Briefly, we summarize the parameters to be taken into account when performing in vitro cell assays, in order to obtain reliable and reproducible results, which was fundamentally discussed by lecturers at the educational course on preclinical and early-phase clinical pharmacology studies, at the 40th Winter Meeting of the Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. Moreover, specific cellular sensitivity tests are described. In addition to monolayer in vitro cell models for the screening of new potential candidate drugs, three-dimensional tumor/cell tissue models are emerging as new pre-clinical tools that more closely reflect the in vivo microenvironment. Therefore, the use of different in vitro models for drug screening can enhance the predictability and reliability of pre-clinical drug-discovery phases and target validation.
基于细胞的体外检测的一个目的是确定最佳的候选药物，以便使用最佳的肿瘤细胞模型进行开发。在每个抗癌药物发现过程中，这都是具有挑战性的。简要地说，我们总结了在进行体外细胞检测时需要考虑的参数，以获得可靠和可重复的结果，这在欧洲癌症研究与治疗组织的药理学和分子机制小组第 40 届冬季会议上的临床前和早期临床药理学研究教育课程中，由讲师进行了基本讨论。此外，还描述了特定的细胞敏感性测试。除了用于筛选新的潜在候选药物的单层体外细胞模型外，三维肿瘤/细胞组织模型作为新的临床前工具正在出现，这些模型更能反映体内微环境。因此，使用不同的体外模型进行药物筛选可以提高临床前药物发现阶段和靶标验证的可预测性和可靠性。
